|Written by Rob Goldman|
The info in this week’s edition of The Goldman Guide is important not just for this week, but heading into mid-May. With that in mind, here are the key topics:
When are we going to learn? About six weeks ago, the stocks hit a new low and the doomsday network was in full swing. Some prognosticators were calling for $20/barrel oil. Investors may not have been panicked, but we were all shaken—big time.
This past week, the Dow Jones Industrial Average closed positive for the year and oil reached around $42/barrel, in intraday trading. So much for doomsday.
Have any of you watched the wall-to-wall college basketball games these past four days? How many times have we seen the improbable become probable? I am not trying to equate stock market performance with basketball games. The lesson to be learned here is to not panic and use rational thought rather than emotions in approaching investments.Look, stocks may have now peaked, according to some forecasters. We, however believe that the oil push has run its course for the most part and earnings, beginning in Q1, will begin to play a big role in stock selection, accumulation and direction (up). However, due to how the calendar plays itself out, there are two things at play which could impact stocks in your portfolio or on your radar screen.
The Stock Market Today
As we near the end of the quarter, we are entering the typical quiet period for many companies and company management. This means that those fun corporate stock buybacks that (in theory) help liquidity, raise stock prices, and lowers shares outstanding will cease for a spell, only to return after financials are released, which will help drive prices higher. We are also entering a period where we run the risk of Q1 negative earnings pre-announcements and a period where some analysts tweak and play with their estimates, causing short term shifts in stock prices.
That’s the bad news.
The good news is that essentially all of the window dressing executed by institutions is likely complete, although it is possible that it is one (small) reason why stocks have enjoyed a good run. What is window dressing? It is when firms do not wish to have big losers on their books at quarter end, which makes them look foolish and would prefer to have winners for the period to make them look oh so smart.
What this means for you are two things. One, now is a good time to buy stocks that have not had big runs and are expected to meet or exceed Q1 expectations, i.e. GARP or value. Two, it means big-time sold off sectors and stocks could be real bottom fishing candidates, now if not very soon. As you will see later in the Guide, health care has sucked wind but there are some oversold situations that we have uncovered.
Small Cap Health Care Sleeper
Please don’t think I am lazy for doing this, but I am not just a fan of MiMedx Group (NASDAQ—MDXG—$8.31) as a stock and company. But, they do such a great job describing what they do I am literally cutting and pasting a section of the following description from their most recent press release:
“MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies are AmnioFix®, EpiFix®, OrthoFlo, Physio™, AlloBurn™, and CollaFix™. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through our donor program, a mother delivering a healthy baby via scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 500,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.”
From the fundamental perspective, the stock looks great. Sales of $187M for 2015 were a record and EPS were $0.26. For 2016 and 2017, Wall Street analysts project a 41% and 26% sales increase, respectively with EPS reaching $0.33 this year (up 27%) and EPS of $0.44 next year. At current levels, the stock trades at a reasonable 25x P/E considering the strong expected growth. Plus, the company has a history of beating estimates, which happen to be on the rise.
Technically, MDXG is down 11% for the year, 37% below its 52 week high and now trades below its key moving averages. We think the technicals should be ignored and that the stock will rock come May when it reports Q1 results. Our target is $11, which is still well below its year high and is just a slight premium to its projected EPS growth rate.
Great info, insights, and hard-hitting stories make up this week’s Say What? feature...
Maybe a precursor of a shoe to drop a few quarters ahead?
The New York Times
Millennials running the show? Sooner than you think.
To self-drive or not to self-drive…
Dovetails with our missives of late.
I don’t 100% buy it, but prices may have gotten ahead of themselves.
AAII Sentiment Survey (figures rounded)
Want proof that there is no conviction in this market? The Dow Jones Industrial Average and S&P 500 Index hit new highs for the year and the percentage of bulls declined in both the AAII and TickerSense surveys. Or maybe the figures are low because health care continues to take it on the chin and the market has been led by materials, financials, and industrials the past month, rather than the sexy technology, consumer, and health care sectors. Frankly, until that sector turns, and it is down 9% YTD, I see some headwinds in lengthening the current upward cycle. It will happen, but it won’t be easy. Over 38% or 287 of the 754 health care stocks tracked by Finviz.com are down at least 25% YTD. Wow.
1498 Reisterstown Road, Suite 286 Baltimore Maryland 21208 Phone: 410.609.7100
Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, unless noted, With some exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ. Goldman Small Cap Research members and contributors’ bios, certifications, and experience can be found on our website: www.goldmanresearch.com
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces non-sponsored and sponsored (paid) investment research. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The Firm’s non-sponsored research publications category, Select Research, reflects the Firm’s internally generated stock ideas, along with economic, industry and market outlooks. In virtually all cases, stocks mentioned in Select Research offerings are listed on the NYSE or the NASDAQ. Publications in this category include the weekly newsletter The Goldman Guide, Market Monitor blogs, Special Reports, and premium products such as The 30-30 Report. Goldman Small Cap Research analysts are neither long nor short stocks mentioned in this newsletter.
Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in company-specific Opportunity Research reports, updates and articles.
Goldman Small Cap Research has not been compensated for any content in this issue.
All information contained in this newsletter and in our reports were provided by the companies mentioned via news releases, filings, and their websites or generated from our own due diligence. Economic, market data and charts are provided by a variety of sources and are cited upon publication. Stock performance data and information are derived from Yahoo! Finance and other websites or sources, as noted. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, other firms, or other financial news outlets. Goldman Small Cap Research relied solely upon information provided by companies through filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, blog, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the company featured in this newsletter, we may from time to time include our own opinions about the companies profiled herein, their businesses, markets and opportunities. Any opinions we may offer about the companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.